Data2Discovery Inc
Data2Discovery Inc is a biotechnology and data science company specializing in AI-driven drug discovery and disaster medicine solutions.
Profile
Uses AI and data science to discover treatments for infectious diseases and improve disaster response.
Data2Discovery Inc is a biotechnology and data science company specializing in AI-driven drug discovery and disaster medicine solutions. Founded in 2017 and led by CEO Shelley London, the company leverages its patent-pending knowledge graph technology to analyze complex datasets for breakthroughs in infectious diseases and emergency response. Notable achievements include identifying a potential treatment for Mycobacterium Abscessus Complex and securing a $2.3 million US Army contract with Indiana University for disaster medicine research.
The company has received a $750,000 NSF SBIR Phase II grant, indicating federal recognition of its technological capabilities. While specific revenue figures are undisclosed, its partnerships with academic institutions and government agencies suggest a stable funding trajectory. Data2Discovery operates at the intersection of AI and life sciences, focusing on high-impact, difficult-to-treat conditions.
Who buys this
- Pharmaceutical companies seeking novel drug candidates
- Government agencies funding biomedical research
- Academic institutions collaborating on data-driven research
- Healthcare organizations tackling infectious diseases
Publicly disclosed clients
- Indiana University
- US Army
Strengths and what to watch
Strengths
- Proprietary knowledge graph technology for integrating heterogeneous data sources
- Demonstrated success in identifying potential treatments for rare infections
- Strong partnerships with academic and government entities
Watch for
- Dependence on government grants and contracts for funding
- Unproven scalability of drug discovery pipeline beyond early-stage research
- Intellectual property risks in competitive AI-driven biotech space
Key Information
- Founded
- 2017
Frequently Asked Questions
What does Data2Discovery Inc do?
Data2Discovery uses AI and data science to accelerate drug discovery for infectious diseases and improve disaster response. Their patent-pending knowledge graph technology analyzes complex datasets to identify potential treatments, with demonstrated success against Mycobacterium Abscessus Complex. The company partners with government and academic institutions.
How does Data2Discovery's AI technology work?
The company's proprietary knowledge graph technology integrates diverse data sources to uncover patterns in biomedical research. This AI system identifies potential drug candidates by analyzing relationships between biological entities, particularly for difficult-to-treat infections and emergency medicine scenarios.
What diseases has Data2Discovery researched?
Data2Discovery has identified a potential treatment for Mycobacterium Abscessus Complex, a rare infection resistant to antibiotics. Their AI platform specializes in analyzing complex infectious diseases, with applications in tuberculosis research and other conditions requiring advanced data integration.
Who funds Data2Discovery's research?
The company has secured a $2.3 million US Army contract for disaster medicine research and a $750,000 NSF SBIR Phase II grant. These federal awards complement partnerships with Indiana University and other academic institutions, indicating strong government confidence in their technology.
What are the risks of Data2Discovery's approach?
Challenges include reliance on government funding, unproven scalability beyond early research phases, and intellectual property competition in AI biotech. Their knowledge graph technology shows promise but must demonstrate commercial viability against established drug discovery methods.
Who are Data2Discovery's key partners?
Notable collaborators include Indiana University for academic research and the US Army for disaster medicine applications. The company works with pharmaceutical firms seeking novel drug candidates and healthcare organizations tackling complex infectious diseases through data-driven approaches.
Sources
- www.d2discovery.com — Mycobacterium treatment discovery
- www.d2discovery.com — $2.3m US Army contract
- www.d2discovery.com — NSF SBIR Phase II grant
- www.linkedin.com — CEO background